Research programme: melanotransferrin conjugated therapeutics - biOasis/MedImmune

Drug Profile

Research programme: melanotransferrin conjugated therapeutics - biOasis/MedImmune

Latest Information Update: 09 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer biOasis Technologies; MedImmune
  • Class Drug conjugates
  • Mechanism of Action Biological transport stimulants; Transferrin-binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 12 May 2015 Preclinical trials in Neuropathic pain in Canada (Parenteral)
  • 12 May 2015 Preclinical pharmacodynamics and pharmacokinetics data in Neuropathic pain released by biOasis Technologies
  • 17 Mar 2014 MedImmune and biOasis enters into a license agreement for second generation versions of biOasis' Transcend™ technology platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top